Table 2. Outcomes among of COVID-19 positive inpatients treated with baricitinib / remdesivir / dexamethasone.
Percentages may not total 100 because of rounding.
| Patient Outcomes | |||
|---|---|---|---|
| All Patients | |||
| Primary Outcomes: | |||
| Mortality over first 7-days following admission – no. (%) | 2 | (4.4) | |
| Mortality over entire hospitalization? – no. (%) | 6 | (13.3) | |
| Secondary Outcomes: | |||
| Diagnosis of hemodynamic shock during hospitalization – no. (%) | 4 | (8.9) | |
| Thrombosis during hospitalization – no. (%) | - | ||
| Need for vasopressor support during hospitalization – no. (%) | 4 | (8.9) | |
| Average duration of vasopressor support care during hospitalization – days | 1.5 | ||
| New oxygen requirement during hospitalization – no. (%) | 45 | (100.0) | |
| Average duration of new oxygen requirement (days) | 7.9 | ||
| Need for non-invasive ventilation – no. (%) | 19 | (42.2) | |
| Average duration of non-invasive ventilation (days) | 5.1 | ||
| Need for mechanical ventilation during hospitalization – no. (%) | 4 | (8.9) | |
| Average duration of mechanical ventilation during hospitalization (days) | 3.75 | ||
| Duration of hospitalization (days) | 11 | ||
| Estimated duration of illness (days) | 15 | ||
| Discharge status - | |||
| Home or self care – no. (%) | 26 | (57.8) | |
| Home with home health services – no. (%) | 5 | (11.1) | |
| Subacute rehab – no. (%) | 4 | (8.9) | |
| Skilled nursing facility – no. (%) | 2 | (4.4) | |
| Transfer to another facility – no. (%) | 2 | (4.4) | |
| Deceased – no. (%) | 6 | (13.3) | |